AstraZeneca (AZN) said Monday its investigational drug AZD0780 combined with standard-of-care statins reduced low-density lipoprotein, or LDL, cholesterol by 50.7% at 12 weeks in a phase 2b trial, with no need for fasting or food restrictions.
Among participants receiving AZD0780 30mg, 84% reached the recommended LDL-C target of under 70 mg/dL, compared with 13% on statins alone, the company said.
Elevated LDL-C is a known risk factor for serious cardiovascular conditions like heart attacks and strokes.
AZD0780 was generally well tolerated in the trial, with similar rates of adverse events and treatment discontinuation between the treatment and placebo groups, according to the company.
Price: 72.94, Change: -0.86, Percent Change: -1.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。